EATONTOWN, N.J., Oct. 13 /PRNewswire-FirstCall/ -- Osteotech, Inc.
(Nasdaq: OSTE), a leader in the emerging field of biologic products
for regenerative healing, announced today that it has received
notification that the U.S. Department of Justice and Federal
Trade Commission granted early termination of the Hart-Scott-Rodino
waiting period for its proposed merger with Medtronic, Inc.
The closing of the merger remains subject to antitrust
clearance in foreign jurisdictions and approval by Osteotech
stockholders at the special meeting to be held on November 9, 2010, as well as other customary
closing conditions.
About Osteotech
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in
providing biologic solutions for regenerative medicine to support
surgeons and their patients in the repair of the musculoskeletal
system through the development of innovative therapy-driven
products that alleviate pain, promote biologic healing and restore
function. For further information regarding Osteotech, please
go to Osteotech's website at www.osteotech.com.
Additional Information about the Proposed Transaction and
Where You Can Find It
Osteotech has filed with the Securities and Exchange Commission
(the "SEC") a definitive proxy statement in connection with the
proposed acquisition of Osteotech by Medtronic. The
definitive proxy statement is being mailed to Osteotech
stockholders on October 14, 2010.
Before making any voting or investment decisions with respect
to the transaction, investors and stockholders of Osteotech are
urged to read the proxy statement when it becomes available because
it contains important information about the transaction, Osteotech
and Medtronic. Investors and stockholders may obtain free
copies of the definitive proxy statement and other documents filed
with the SEC at the SEC's web site at www.sec.gov. In
addition, investors and stockholders may obtain free copies of the
documents filed with the SEC by accessing Osteotech's website at
www.osteotech.com or by writing Osteotech to the attention of the
Assistant Secretary at 51 James Way, Eatontown, New Jersey, 07724.
Information Regarding Participants
Osteotech, Medtronic and their respective directors, executive
officers and certain other members of management and employees may
be soliciting proxies from Osteotech stockholders in favor of the
merger. Information regarding the persons who may, under the
rules of the SEC, be considered participants in the solicitation of
the Osteotech stockholders in connection with the proposed merger
will be set forth in the proxy statement when it is filed with the
SEC. You can find information about Medtronic's executive
officers and directors in its definitive proxy statement filed with
the SEC on July 16, 2010. You
can obtain a free copy of this document at the SEC's web site at
www.sec.gov, or by accessing Medtronics's website at
www.Medtronic.com and clicking on the Investors link. You can
find information about Osteotech's executive officers and directors
in its definitive proxy statement filed with the SEC August 3, 2010. You can obtain a free copy
of this document at the SEC's web site at www.sec.gov or by
accessing Osteotech's website at www.osteotech.com or by writing
Osteotech to the attention of the Assistant Secretary at 51 James
Way, Eatontown, New Jersey,
07724.
SOURCE Osteotech, Inc.
Copyright . 13 PR Newswire